The role of pemetrexed (Alimta®, LY231514) in lung cancer therapy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Pemetrexed (Alimta®, LY231514) is a new multitargeted antifolate that inhibits several enzymes involved in the folate pathway. Pemetrexed is a potent inhibitor of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small-cell lung cancer (NSCLC) as well as in a broad array of other solid tumors including mesothelioma and breast, colorectal, bladder, cervical, gastric, and pancreatic cancer. In NSCLC, single-agent activity has been documented in the first- and second-line settings. Promising activity has also been demonstrated when pemetrexed is combined with cisplatin, vinorelbine, oxaliplatin, carboplatin, and gemcitabine. Low-level dietary supplement of folic acid and vitamin B12 has significantly improved the safety profile of pemetrexed without compromising its antitumor effect. In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalClinical Lung Cancer
Volume5
Issue number1
StatePublished - Jul 2003

Fingerprint

Pemetrexed
Lung Neoplasms
Non-Small Cell Lung Carcinoma
oxaliplatin
Therapeutics
gemcitabine
Folic Acid
Hydroxymethyl and Formyl Transferases
Folic Acid Antagonists
Clinical Pharmacology
Carboplatin
Mesothelioma
Vitamin B 12
Dietary Supplements
Pancreatic Neoplasms
Urinary Bladder Neoplasms
Uterine Cervical Neoplasms
Cisplatin
Stomach Neoplasms
Colorectal Neoplasms

Keywords

  • 5-Flourouracil
  • Folic acid
  • Multitargeted antifolate
  • Thymidylate synthase
  • Vitamin B

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

The role of pemetrexed (Alimta®, LY231514) in lung cancer therapy. / Molina, Julian R; Adjei, Alex.

In: Clinical Lung Cancer, Vol. 5, No. 1, 07.2003, p. 21-27.

Research output: Contribution to journalArticle

@article{713f3b6eee4d4060a27b411ac3bd71d7,
title = "The role of pemetrexed (Alimta{\circledR}, LY231514) in lung cancer therapy",
abstract = "Pemetrexed (Alimta{\circledR}, LY231514) is a new multitargeted antifolate that inhibits several enzymes involved in the folate pathway. Pemetrexed is a potent inhibitor of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small-cell lung cancer (NSCLC) as well as in a broad array of other solid tumors including mesothelioma and breast, colorectal, bladder, cervical, gastric, and pancreatic cancer. In NSCLC, single-agent activity has been documented in the first- and second-line settings. Promising activity has also been demonstrated when pemetrexed is combined with cisplatin, vinorelbine, oxaliplatin, carboplatin, and gemcitabine. Low-level dietary supplement of folic acid and vitamin B12 has significantly improved the safety profile of pemetrexed without compromising its antitumor effect. In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed.",
keywords = "5-Flourouracil, Folic acid, Multitargeted antifolate, Thymidylate synthase, Vitamin B",
author = "Molina, {Julian R} and Alex Adjei",
year = "2003",
month = "7",
language = "English (US)",
volume = "5",
pages = "21--27",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The role of pemetrexed (Alimta®, LY231514) in lung cancer therapy

AU - Molina, Julian R

AU - Adjei, Alex

PY - 2003/7

Y1 - 2003/7

N2 - Pemetrexed (Alimta®, LY231514) is a new multitargeted antifolate that inhibits several enzymes involved in the folate pathway. Pemetrexed is a potent inhibitor of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small-cell lung cancer (NSCLC) as well as in a broad array of other solid tumors including mesothelioma and breast, colorectal, bladder, cervical, gastric, and pancreatic cancer. In NSCLC, single-agent activity has been documented in the first- and second-line settings. Promising activity has also been demonstrated when pemetrexed is combined with cisplatin, vinorelbine, oxaliplatin, carboplatin, and gemcitabine. Low-level dietary supplement of folic acid and vitamin B12 has significantly improved the safety profile of pemetrexed without compromising its antitumor effect. In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed.

AB - Pemetrexed (Alimta®, LY231514) is a new multitargeted antifolate that inhibits several enzymes involved in the folate pathway. Pemetrexed is a potent inhibitor of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small-cell lung cancer (NSCLC) as well as in a broad array of other solid tumors including mesothelioma and breast, colorectal, bladder, cervical, gastric, and pancreatic cancer. In NSCLC, single-agent activity has been documented in the first- and second-line settings. Promising activity has also been demonstrated when pemetrexed is combined with cisplatin, vinorelbine, oxaliplatin, carboplatin, and gemcitabine. Low-level dietary supplement of folic acid and vitamin B12 has significantly improved the safety profile of pemetrexed without compromising its antitumor effect. In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed.

KW - 5-Flourouracil

KW - Folic acid

KW - Multitargeted antifolate

KW - Thymidylate synthase

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=0043066790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043066790&partnerID=8YFLogxK

M3 - Article

C2 - 14596699

AN - SCOPUS:0043066790

VL - 5

SP - 21

EP - 27

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -